We are committed to improving and expanding access to COVID-19 therapeutics for our neighbors that are unequally impacted by the pandemic.

The COVID-19 pandemic has worsened existing health inequities in the United States, especially for people who are low income, over the age of 50, Black, Latinx, speak a primary language other than English, or experience visible or invisible disabilities. Systems of power (e.g. racism, classism, and xenophobia) have caused inequities that continually exclude these folks from fair and just access to healthcare services. In turn, these inequities increase their risk of hospitalization and death from COVID-19.

With reliable and effective treatment available for COVID-19, it’s important we ensure equitable access for all. We must invest in serving communities who are high risk for COVID-19 complications.

Facilitating quick access to COVID-19 treatment– including developing test-to-treat pathways within the therapeutic window–  has been a complex challenge. Facilitating equitable access to COVID-19 treatment was a major opportunity to work with providers to establish a stronger foundation for lasting change in California’s healthcare systems.